Roctavian, Potential Hemophilia A Gene Therapy, Get Fresh FDA Support
News
The U.S. Food and Drug Administration (FDA) has given regenerative medicine advanced therapy (RMAT) designation to Roctavian, an investigational gene therapy by BioMarin Pharmaceutical for severe hemophilia A. The designation is “a ... Read more